Article
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.
Cancer immunology research - 1 Nov 2016
Johnson Douglas B, Frampton Garrett M, Rioth Matthew J, Yusko Erik, Xu Yaomin, Guo Xingyi, Ennis Riley C, Fabrizio David, Chalmers Zachary R, Greenbowe Joel, Ali Siraj M, Balasubramanian Sohail, Sun James X, He Yuting, Frederick Dennie T, Puzanov Igor, Balko Justin M, Cates Justin M, Ross Jeffrey S, Sanders Catherine, Robins Harlan, Shyr Yu, Miller Vincent A, Stephens Philip J, Sullivan Ryan J, Sosman Jeffrey A, Lovly Christine M
Abstract excerpt
Therapeutic antibodies blocking programmed death-1 and its ligand (PD-1/PD-L1) induce durable responses in a substantial fraction of melanoma patients. We sought to determine whether the number and/or type of mutations identified using a next-generation sequencing (NGS) panel available in the clinic was correlated with response to anti-PD-1 in melanoma. Using archival melanoma samples from anti-PD-1/PD-L1-treated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
